chlorophenyl)-2-(4-piperidyl)-tetrahydrofuran], the most promising representative of a new chemical family of antimalarial agents (3), had substantial activity against infections with trophozoites of Plasmodium berghei in mice. Measured by the dose required to suppress parasitemia by 90%, BA-41,799 was approximately 1/4 as active as chloroquine, 1/2 as active as cycloguanil, and 1/80 as active as pyrimethamine against infections with a drug-susceptible strain of this plasmodium. By the same yardstick, BA-41,799 was essentially as active against infections with a variant strain that was 60-fold resistant to chloroquine as it was against infections with the parent susceptible strain. Against a variant strain that was 800-fold resistant to cycloguanil, it was only one-fifth as active as it was against the parent strain, an indication, albeit quite limited, of cross-resistance to an antifol. BA-41,799 also had the capacity to prevent infections in mice challenged with sporozoites of a drug-susceptible strain (5) of Plasmodium berghei yoelii. These observations attracted the attention of those responsible for the Malaria Research Program of the U.S. Department of the Army at the Walter Reed Army Institute of Research. This led to the synthesis of substantial numbers of compounds structurally related to BA-41,799 and to evaluations of their activities against infections with trophozoites of P. berghei in mice and sporozoites of Plasmodium gallinaceum in chickens (1) . None of these compounds displayed activities superior to those of BA-41,799 in these test systems (1, 4) .
In late September 1966, stimulated by a review of data on the activities of BA-41,799 against infections with diverse strains of P. berghei (made available on 23 August 1966 by Wallace Peters, Ciba Ltd., Basel, Switzerland, and identical with those referred to above [5] ), my laboratories undertook evaluations of the prophylactic, radical curative, and blood schizonticidal activities of this tetrahydrofuran against infections with Plasmodium cynomolgi in rhesus monkeys. Spe-cial attention was given to the impact of pyrimethamine resistance on these activities. Publication of the results of these studies, less promising in import than those on infections with P. berghei, was deferred, first because of concerns of others with patent protection, later because of personal preoccupation with high-priority studies on infections with human plasmodia in owl monkeys (6) . They are now being recorded in this brief report so as to complete the picture on what is currently known of the activity and potential of BA-41,799 as an antimalarial agent.
MATERIALS AND METHODS
All of the procedures pertinent to conduct of the experiments included in this report have been detailed previously (11) (12) (13) 15) . The methodologies described cover: (i) the acquisition of feral monkeys, their conditioning for experimental use, and their maintenance and handling during therapeutic and other experiments; (ii) the routine maintenance of diverse stock strains of P. cynomolgi by serial monkey-tomosquito-to-monkey passages; (iii) the acquisition of mosquitoes (Anophelesfreeborni) heavily infected with sporozoites; (iv) the initiation of infections with sporozoites or trophozoites; (v) the monitoring of parasitic events in both untreated and treated infections, including ascertaining when infections are self-limited or cured; and (vi) the origins of the drug-susceptible Ro and the pyrimethamine-resistant RolPM strains used in the current investigation, the courses of untreated sporozoite-and trophozoite-induced infections with these strains, and the responses of such infections to treatment with standard drugs, including chloroquine, pyrimethamine, chlorguanide, quinine, and primaquine.
The studies presented here were served by 42 feral juvenile rhesus monkeys (Macaca mulatta), males ranging from 2.6 to 3.9 kg in weight at time of assignment to experiment. Of this total, 26 were inoculated with sporozoites: 13 with the Ro strain and 13 with the RolPM strain. The inocula were 7.5 x 105 and 2.3 x 105 sporozoites for challenges with the respective strains. The remaining 16 monkeys were inoculated with trophozoites: eight with the Ro strain and eight with the RolPM strain. In both cases, the inoculum was 5 x 105 trophozoites. Routine monitoring of parasitic events in the prophylactic study was initiated on day 7 after sporozoite challenge and repeated daily throughout the evaluation period. As the results summarized in Table 1 show, BA-41,799 provided no protection against infections with sporozoites of the Ro strain at doses of 1.0 or 5.0 mg/kg and effected only a 9-to 11-day delay in onset of parasitemia at a dose of 25.0 mg/kg. This summary also shows that BA-41,799 was completely without effect on development of infections with the RolPM strain. Thus, at all dose levels, from 1.0 to 25.0 mg/kg, parasitemias became patent on day 8 after sporozoite challenge, the same time as in the untreated control. In keeping with previous experience (14, 16) , primaquine at a dose of 1.0 mg/kg provided full protection against infections with sporozoites of both the Ro and RolPM strains.
Assessment of radical curative activity. The capacity of BA-41,799 to effect radical cure was evaluated against the infections that developed in the 18 monkeys who had received this tetrahydrofuran in the prophylactic regimen with little or no benefit. Doses of 1.0, 5.0, or 25.0 mg/kg were administered once daily for 7 days to subgroups of three monkeys formed by inclusion of one subject from each of the subgroups in the prophylactic experiment. Treatment was initiated on day 3 or 4 after the onset of patency, when parasitemias of 10 to 50 parasites per 104 erythrocytes prevailed. Administration of BA-41,799 was followed by dosage with chloroquine, 5.0 mg/kg daily for 7 days, whenever parasitemia persisted or upon relapse after apparent clearance of parasitemia. This was done to ensure that the effects of BA-41,799 on the exoerythrocytic stages were not being masked by persisting parasitemia. All infections that relapsed subsequent to this course of chloroquine were retreated with the potentially curative (10, 14, 16) combination of primaquine and chloroquine at doses of 0.75 and 5.0 mg/kg, respectively, once daily for 7 days.
The results of the above study (Table 2) show that, over the range of doses tested, BA-41,799 did not effect cure of infections with either the Ro or RolPM strain. Doses of 25.0 mg/kg led to temporary clearance of parasites of the Ro strain but not those of the RolPM strain. In only one subject, a monkey infected with the RolPM strain, was there a significant lengthening of the interval between the end of treatment with chloroquine and relapse, a phenomenon for which no explanation can be offered. As would have been expected (10, 14, 16) , all 18 infections not cured by 799 were cured by the primaquine-chloroquine regimen.
Assessment of blood schizonticidal activity. Of the 16 monkeys inoculated with trophozoites (8 with the Ro strain and 8 with the RolPM strain), two infected with each strain served as untreated controls (Fig. 1D) . Treatment (Fig. 1A and B). These doses were without effect on the parasitemias of monkeys infected with the RoIPM strain. Doses of 100.0 mg/kg were lethal for three of four recipients, one of the two infected with the Ro strain and both of those infected with the RolPM strain (Fig. 1C) . These subjects died approximately 28 h after the second, third, or sixth dose, exhibiting severe depression, somnolence, and collapse of peripheral circulation 16 to 30 h antemortem. The infection of the fourth recipient of the 100.0-mg/kg dose, a subject infected with the Ro strain, was cured.
DISCUSSION
There is little that can be added to the above descriptions of the failure of BA-41,799 to effect prophylaxis, radical cure, or suppressive cure of infections with either the drug-susceptible Ro strain or the pyrimethamine-resistant RolPM strain of P. cynomolgi. These negative results dim prospects for successful use of this tetrahydrofuran in the treatment of human malaria, its interesting and substantial accomplishments in mice infected with P. berghei or P. berghei yoelii notwithstanding. The past predictive records of these rodent infections, especially as they pertain to prophylaxis and cure of human infections with Plasmodium vivax, are poor (9) , whereas those of infections with P. cynomolgi in rhesus monkeys are excellent (9) . It can be argued that infections with trophozoites of P. berghei predict reasonably well for infections with Plasmodium falciparum (8 799 that equalled the latter agent in activity against infections with sporozoites of P. gallinaceum in chickens and trophozoites of P. berghei in mice (4), effected no more than temporary clearance of parasitemia when administered at maximum tolerated doses to owl monkeys infected with trophozoites of the pyrimethamine-susceptible, chloroquineresistant Oak Knoll strain of P. falciparum (7; unpublished data).
In view of the negative results of this study, one could argue that investigation of the tetrahydrofurans as antimalarial agents could well be terminated at this point. Such a position seems premature. It would seem wiser to recognize that infections with P. berghei have little to offer to evaluations of the potentials of representatives of this class of compounds and turn to a more predictive system for monitoring the products of systematic chemical syntheses. As pointed out previously (9) , when manipulated judiciously, the P. cynomolgi-rhesus monkey model is neither so costly nor unwieldy that it cannot be used for drug screening, even though it is more expensive and demanding of personnel attention than the P. berghei-mouse model.
